EQ vs ZURA
EQ: A clinical-stage biotechnology company developing novel aryl hydrocarbon receptor (AhR) modulators for autoimmune and inflammatory diseases. ZURA: Zura Bio is developing differentiated bispecific and monoclonal antibodies targeting immune pathways in autoimmune and inflammatory diseases where current therapies leave patients with inadequate disease control.
Side-by-side fundamentals
| Metric | EQ | ZURA | Edge |
|---|---|---|---|
| Price as of 2026-08-04 close | $2.26 | $5.69 | |
| Market cap as of 2026-08-05 | $143M | $541M | |
| PEG as of 2026-08-04 | n/a | -0.34 | |
| Net margin as of 2026-08-05 | -19.6% | n/a | |
| Operating margin as of 2026-08-05 | -20.1% | n/a | |
| ROE as of 2026-08-05 | -61.4% | -54.0% | ZURA higher |
| ROA as of 2026-08-05 | -53.7% | -46.3% | ZURA higher |
| Debt / equity as of 2026-08-05 | 0.00 | 0.00 | Tie |
| Revenue CAGR (3y) SEC XBRL | +61.5% | n/a | |
| Beta as of 2026-08-05 | 1.94 | 1.42 | |
| 1-year return as of 2026-08-04 close | +303.6% | +289.7% | EQ higher |
Fundamentals: market data, as of 2026-08-05. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-04.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.